会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • 세균내DNA 또는 RNA로부터 리포폴리사카라이드를제거하는 방법
    • 세균내DNA또는RNA로부리포폴리사카라이드를제거하는방
    • KR100463415B1
    • 2004-12-23
    • KR1020010078665
    • 2001-12-12
    • 씨제이 주식회사
    • 고형곤김연향전용감송후근박완제
    • C07H1/06
    • PURPOSE: A method for removing lipopolysaccharides(LPS) from DNA or RNA in a cell is provided, thereby easily removing the lipopolysaccharides from cellular DNA or RNA. CONSTITUTION: A method for removing lipopolysaccharides(LPS) from DNA or RNA in a cell is characterized by using the difference of precipitation between lipopolysaccharides(LPS) and DNA according to the change of alcohol content, wherein lipopolysaccharides(LPS) are removed when the alcohol content is low and bacterial DNA or RNA precipitates are obtained by the addition of alcohol to the supernatant; the alcohol is methanol, ethanol or isopropanol; and the lipopolysaccharides(LPS) are removed by adding the alcohol into a sample of DNA or RNA and centrifuging it at 5,000 to 15,000 rpm and 0 to 30 deg. C for 1 sec to 72 hours.
    • 目的:提供一种从细胞中的DNA或RNA去除脂多糖(LPS)的方法,由此容易地从细胞DNA或RNA中去除脂多糖。 构成:根据醇含量的变化,利用脂多糖(LPS)和DNA之间的沉淀差异来表征从细胞中的DNA或RNA去除脂多糖(LPS)的方法,其中脂肪多糖(LPS)在醇 含量低,通过向上清液中加入醇得到细菌DNA或RNA沉淀; 醇为甲醇,乙醇或异丙醇; 通过将醇加入DNA或RNA样品中并以5,000至15,000rpm和0至30℃离心来去除脂多糖(LPS)。 C 1秒至72小时。
    • 4. 发明公开
    • 테트라싸이클린 유도 발현 체계를 이용한 Cdc25B2또는 Cdc25B3을 과발현하는 형질전환T-Rex-HeLa 세포주
    • CDC25B2-或CDC25B3-使用四环素诱导表达系统的过表达变体T-REX-HELA
    • KR1020040067521A
    • 2004-07-30
    • KR1020030004654
    • 2003-01-23
    • 씨제이 주식회사
    • 전용감이장윤김해선하경식손영선박완제
    • C12N15/86
    • C12N15/85C12N5/0693C12N15/70
    • PURPOSE: Cdc25B2- or Cdc25B3-overexpressing transformants T-Rex-HeLa using tetracycline-inducible expression system are provided, which transformants are useful for studies on Cdc25B2 and Cdc25B3, and development of anticancer drugs targeting anticancer gene including Cdc25B2 and Cdc25B3. CONSTITUTION: A recombinant expression vector pcDNA4/TO+Cdc25B2 contains human cytomegalovirus promoter, tetracycline operator, Cdc25B2 gene and ampilicin- and zeocin-resistant gene. A recombinant expression vector pcDNA4/TO+Cdc25B3 contains human cytomegalovirus promoter, tetracycline operator, Cdc25B3 gene and ampilicin- and zeocin-resistant gene. An animal cell line CJ52001(kCLRF-BP-00073) which induces overexpression of Cdc25B2 gene with tetracycline is produced by transforming a cell line T-Rex-HeLa with the recombinant expression vector pcDNA4/TO+Cdc25B2. An animal cell line CJ52002(kCLRF-BP-00074) which induces overexpression of Cdc25B3 gene with tetracycline is produced by transforming a cell line T-Rex-HeLa with the recombinant expression vector pcDNA4/TO+Cdc25B3.
    • 目的:提供使用四环素诱导型表达系统的Cdc25B2-或Cdc25B3-过表达转化体T-Rex-HeLa,该转化体可用于Cdc25B2和Cdc25B3的研究,并开发靶向抗癌基因(包括Cdc25B2和Cdc25B3)的抗癌药物。 构成:重组表达载体pcDNA4 / TO + Cdc25B2含有人巨细胞病毒启动子,四环素操作子,Cdc25B2基因和安慰剂和zeocin抗性基因。 重组表达载体pcDNA4 / TO + Cdc25B3含有人巨细胞病毒启动子,四环素操作子,Cdc25B3基因和安替霉素和zeocin抗性基因。 通过用重组表达载体pcDNA4 / TO + Cdc25B2转化细胞系T-Rex-HeLa,产生诱导Cdc25B2基因与四环素过度表达的动物细胞系CJ52001(kCLRF-BP-00073)。 通过用重组表达载体pcDNA4 / TO + Cdc25B3转化细胞系T-Rex-HeLa,产生诱导Cdc25B3基因与四环素过度表达的动物细胞系CJ52002(kCLRF-BP-00074)。
    • 5. 发明公开
    • 엑디손 유도 발현 체계를 이용한 Cdc25B2 또는Cdc25B3을 과발현하는 형질전환 EcR-293 세포주
    • CDC25B2-或CDC25B3-使用ECDYSONE-INDUCIBLE EXPRESSION SYSTEM的ECR-293过表达变体
    • KR1020040067520A
    • 2004-07-30
    • KR1020030004653
    • 2003-01-23
    • 씨제이 주식회사
    • 전용감이장윤김해선하경식손영선박완제
    • C12N15/85
    • C12N15/85G01N2500/00
    • PURPOSE: Cdc25B2- or Cdc25B3-overexpressing transformants EcR-293 using ecdysone-inducible expression system are provided, which transformants are useful for studies on Cdc25B2 and Cdc25B3, and development of anticancer drugs targeting anticancer gene including Cdc25B2 and Cdc25B3. CONSTITUTION: A recombinant expression vector pIND+Cdc25B2 contains a minimum promoter, E/GRE hybrid element, Cdc25B2 gene and ampilicin- and neomycin-resistant gene. A recombinant expression vector pIND+Cdc25B3 contains a minimum promoter, E/GRE hybrid element, Cdc25B3 gene and ampilicin- and neomycin-resistant gene. An animal cell line CJ52003(kCLRF-BP-00075) which induces overexpression of Cdc25B2 gene with ponasterone A is produced by transforming a cell line EcR-293 with the recombinant expression vector pIND+Cdc25B2. An animal cell line CJ52004(kCLRF-BP-00076) which induces overexpression of Cdc25B3 gene with ponasterone A is produced by transforming a cell line EcR-293 with the recombinant expression vector pIND+Cdc25B3.
    • 目的:提供Cdc25B2-或Cdc25B3-过表达转化子EcR-293,采用蜕皮激素诱导型表达系统,该转化体可用于Cdc25B2和Cdc25B3的研究,并开发靶向抗癌基因的抗癌药物,包括Cdc25B2和Cdc25B3。 构成:重组表达载体pIND + Cdc25B2含有最小启动子,E / GRE杂交元件,Cdc25B2基因和新霉素和新霉素抗性基因。 重组表达载体pIND + Cdc25B3含有最小启动子,E / GRE杂交元件,Cdc25B3基因和安替霉素和新霉素抗性基因。 通过用重组表达载体pIND + Cdc25B2转化细胞系EcR-293产生诱导Cdc25B2基因与天冬氨酸A过度表达的动物细胞系CJ52003(kCLRF-BP-00075)。 通过用重组表达载体pIND + Cdc25B3转化细胞系EcR-293产生诱导Cdc25B3基因与ponasterone A过度表达的动物细胞系CJ52004(kCLRF-BP-00076)。
    • 6. 发明公开
    • Cdc2 키나제 활성도의 비방사선 검정방법
    • CDC2激酶活性非侵​​袭性测定方法
    • KR1020040042800A
    • 2004-05-20
    • KR1020030062288
    • 2003-09-05
    • 씨제이 주식회사
    • 하경식손영선전용감김해선박완제이장윤
    • G01N33/68
    • PURPOSE: A method for nonradioisotopic assay of Cdc2 kinase activity is provided, thereby resolving problems caused by using radioisotope in the Cdc2 kinase activity assay, so that the Cdc2 kinase activity can be stably and easily assayed. CONSTITUTION: A method for nonradioisotopic assay of Cdc2 kinase activity comprises the steps of: mixing Cdc2 kinase with retinoblastoma protein Rb to phosphorylate the retinoblastoma protein; reacting the retinoblastoma protein with an antibody capable of recognizing phosphorylated serine at amino acid position 795 and around amino acid residues in human retinoblastoma protein Rb; and subjecting the reaction result to Western blotting, wherein the antibody is 795-phospho-Ser detecting antibody.
    • 目的:提供Cdc2激酶活性的非放射性同位素检测方法,从而解决Cdc2激酶活性测定中使用放射性同位素引起的问题,从而可以稳定且容易地测定Cdc2激酶活性。 构成:Cdc2激酶活性的非放射性同位素检测方法包括以下步骤:将Cdc2激酶与视网膜母细胞瘤蛋白Rb混合,使视网膜母细胞瘤蛋白磷酸化; 使视网膜母细胞瘤蛋白与能够识别人类视网膜母细胞瘤蛋白Rb中氨基酸位置795和氨基酸残基周围的磷酸化丝氨酸的抗体反应; 并将该反应结果进行蛋白质印迹,其中抗体为795-磷酸-Ser检测抗体。
    • 8. 发明授权
    • 엑디손 유도 발현 체계를 이용한 Cdc25B2 또는Cdc25B3을 과발현하는 형질전환 EcR-293 세포주
    • 通过Cdc25B2与Cdc25B3结合使用可以使EcR-293세포주세요유환환환환환환환환환
    • KR100469139B1
    • 2005-01-31
    • KR1020030004653
    • 2003-01-23
    • 씨제이 주식회사
    • 전용감이장윤김해선하경식손영선박완제
    • C12N15/85
    • PURPOSE: Cdc25B2- or Cdc25B3-overexpressing transformants EcR-293 using ecdysone-inducible expression system are provided, which transformants are useful for studies on Cdc25B2 and Cdc25B3, and development of anticancer drugs targeting anticancer gene including Cdc25B2 and Cdc25B3. CONSTITUTION: A recombinant expression vector pIND+Cdc25B2 contains a minimum promoter, E/GRE hybrid element, Cdc25B2 gene and ampilicin- and neomycin-resistant gene. A recombinant expression vector pIND+Cdc25B3 contains a minimum promoter, E/GRE hybrid element, Cdc25B3 gene and ampilicin- and neomycin-resistant gene. An animal cell line CJ52003(kCLRF-BP-00075) which induces overexpression of Cdc25B2 gene with ponasterone A is produced by transforming a cell line EcR-293 with the recombinant expression vector pIND+Cdc25B2. An animal cell line CJ52004(kCLRF-BP-00076) which induces overexpression of Cdc25B3 gene with ponasterone A is produced by transforming a cell line EcR-293 with the recombinant expression vector pIND+Cdc25B3.
    • 目的:提供使用蜕皮激素诱导表达系统的Cdc25B2-或Cdc25B3-过表达转化体EcR-293,该转化体可用于研究Cdc25B2和Cdc25B3,以及开发针对包括Cdc25B2和Cdc25B3的抗癌基因的抗癌药物。 构建:重组表达载体pIND + Cdc25B2含有最小启动子,E / GRE杂交元件,Cdc25B2基因和抗新霉素和新霉素基因。 重组表达载体pIND + Cdc25B3含有最小启动子,E / GRE杂交元件,Cdc25B3基因和抗菌素和耐新霉素基因。 通过用重组表达载体pIND + Cdc25B2转化细胞系EcR-293产生诱导Cdc25B2基因与松甾酮A过度表达的动物细胞系CJ52003(kCLRF-BP-00075)。 通过用重组表达载体pIND + Cdc25B3转化细胞系EcR-293产生诱导Cdc25B3基因与松甾酮A过度表达的动物细胞系CJ52004(kCLRF-BP-00076)。
    • 9. 发明公开
    • 세균내DNA 또는 RNA로부터 리포폴리사카라이드를제거하는 방법
    • 从细胞中的DNA或RNA中去除脂多糖(LPS)的方法
    • KR1020030048684A
    • 2003-06-25
    • KR1020010078665
    • 2001-12-12
    • 씨제이 주식회사
    • 고형곤김연향전용감송후근박완제
    • C07H1/06
    • PURPOSE: A method for removing lipopolysaccharides(LPS) from DNA or RNA in a cell is provided, thereby easily removing the lipopolysaccharides from cellular DNA or RNA. CONSTITUTION: A method for removing lipopolysaccharides(LPS) from DNA or RNA in a cell is characterized by using the difference of precipitation between lipopolysaccharides(LPS) and DNA according to the change of alcohol content, wherein lipopolysaccharides(LPS) are removed when the alcohol content is low and bacterial DNA or RNA precipitates are obtained by the addition of alcohol to the supernatant; the alcohol is methanol, ethanol or isopropanol; and the lipopolysaccharides(LPS) are removed by adding the alcohol into a sample of DNA or RNA and centrifuging it at 5,000 to 15,000 rpm and 0 to 30 deg. C for 1 sec to 72 hours.
    • 目的:提供从细胞中的DNA或RNA中除去脂多糖(LPS)的方法,从而容易地从细胞DNA或RNA中除去脂多糖。 构成:从细胞中的DNA或RNA中去除脂多糖(LPS)的方法的特征在于根据醇含量的变化使用脂多糖(LPS)和DNA之间的沉淀差异,其中当醇分解时,脂多糖(LPS)被去除 含量低,通过向上清液中加入醇获得细菌DNA或RNA沉淀; 醇是甲醇,乙醇或异丙醇; 并通过将醇加入DNA或RNA样品中除去脂多糖(LPS),并以5,000至15,000rpm和0至30℃离心。 C 1秒至72小时。
    • 10. 发明授权
    • Cdc25B 포스파타제의 활성도 측정방법 및 이를 이용한Cdc25B 포스파타제 저해제의 검색방법
    • CDC25B磷酸CDC25B的活性测定方法和使用该磷酸酶抑制剂的搜索方法。
    • KR100547584B1
    • 2006-01-31
    • KR1020030091337
    • 2003-12-15
    • 씨제이 주식회사
    • 전용감박재원김해선하경식손영선박완제이장윤
    • C12Q1/42
    • 본 발명은 Cdc25B2 또는 Cdc25B3를 발현하는 HeLa 세포주를 배양하여 얻어진 단백질 추출물과 Cdk1과 결합된 CyclinB의 면역침전체(immunoprecipitant)를 반응시켜 Cdk1의 15번째 티로신 잔기의 탈인산화를 유도한 후, 비방사선 측정방법인웨스턴 블롯팅을 수행하여 Cdk1 키나제의 활성도를 측정하는 단계를 포함하는 Cdc25B 포스파타제의 활성도 측정방법 및 이를 이용한 Cdc25B 포스파타제 저해제의 검색방법을 제공한다. 또한, 본 발명은 Cdc25B2 또는 Cdc25B3를 발현하는 HeLa 세포주를 배양하여 얻어진 단백질 추출물과 Cdk1의 면역침전체를 반응시켜 Cdk1의 탈인산화를 유도한 후, Cdk1의 15번째 티로신 잔기의 탈인산화 정도를 측정하는 단계를 포함하는 Cdc25B 포스파타제의 활성도 측정방법 및 이를 이용한 Cdc25B 포스파타제 저해제의 검색방법을 제공한다.
      본 발명의 검정방법 및 검색방법은 종래에 비특이적인 기질사용으로 인한 Cdc25B 활성도의 부적절한 반영과 재조합 융합 Cdc25B 단백질의 사용으로 인한 사람 Cdc25B의 번역 후 수식화(Post-translational modification) 현상의 결여로 발생하는 특이성의 저하현상을 극복할 수 있다.
      Cdc25B, Cdc25B2 발현 HeLa 세포주, Cdc25B3 발현 HeLa 세포주, Cdk1, CyclinB
    • 后,本发明由细胞周期蛋白B的整个免疫反应唾液与由培养表达Cdc25B2或CDC25B3(immunoprecipitant)的HeLa细胞得到的蛋白提取物和对Cdk1结合导致对Cdk1的第15酪氨酸残基的去磷酸化的,非辐射测量 进行Western印迹的方法是提供一种方法测量CDC25B磷酸酶的包括测量使用相同的对Cdk1激酶和磷酸酶抑制剂CDC25B搜索方法的活性的步骤的活性。 此外,本发明再由蛋白提取物和通过培养表达Cdc25B2或CDC25B3诱导对Cdk1的去磷酸化的HeLa细胞系获得对Cdk1的整个免疫反应唾液,以测量对Cdk1的酪氨酸残基的去磷酸化15水平 CDC25B磷酸法活动测量,包括以下步骤,并提供了使用相同的CDC25B磷酸酶抑制剂方法的选择。